证券代码：002453 证券简称：华软科技 公告编号：2025-038 金陵华软科技股份有限公司 名 称：沧州奥得赛化学有限公司 类 型：有限责任公司(非自然人投资或控股的法人独资) 住 所：沧州临港开发区西区、经四路东侧 关于控股子公司以债转股方式向其全资子公司增资 的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对 公告中的虚假记载、误导性陈述或者重大遗漏承担责任。 金陵华软科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开第七届董事会第二次会议审议通过了《关于控股子公司 以债转股方式向其全资子公司增资的议案》，同意公司控股子公司北 京奥得赛化学有限公司（以下简称"奥得赛化学"）以债转股方式向 其全资子公司沧州奥得赛化学有限公司（以下简称"沧州奥得赛"） 进行增资。现将详细内容公告如下： 一、增资情况概述 为有效改善沧州奥得赛的资本结构，公司控股子公司奥得赛化学 拟以所持有的沧州奥得赛 13,000 万元债权向沧州奥得赛进行增资， 本次增资完成后奥得赛化学对沧州奥得赛的出资额为 15,000 万元， 占沧州奥得赛注册资本的 100%。 本事项不涉及关联交易，不构成《上 ...

Core Viewpoint - The company plans to increase its capital in its wholly-owned subsidiary, Anhui Haoyuan Pharmaceutical Co., Ltd., through a debt-to-equity conversion to alleviate financial pressure and optimize its capital structure [4][6][7]. Summary by Sections 1. Basic Situation of the Capital Increase - The company has formed a fundraising debt of RMB 40 million from Anhui Haoyuan due to the completion of the "Anhui Haoyuan Biological Pharmaceutical R&D Center Construction Project" in 2021 [1]. - For the "Anhui Haoyuan Annual Production of 121.095 Tons of Pharmaceutical Raw Materials and Intermediates Construction Project (Phase I)," the company has a fundraising debt of RMB 527.26 million and a self-funding debt of RMB 164.53 million [2]. 2. Approval Process - The company’s board of directors approved the use of RMB 180 million of raised funds for capital increase on July 12, 2021, and later approved a debt-to-equity conversion of RMB 200 million on March 22, 2024 [3][4]. 3. Purpose and Impact of the Capital Increase - The capital increase aims to relieve Anhui Haoyuan's financial pressure, optimize its asset-liability structure, and enhance its competitive strength [6][7]. - After the capital increase, Anhui Haoyuan's registered capital will rise from RMB 400 million to RMB 800 million, and it will remain a wholly-owned subsidiary of the company [4][7]. 4. Financial Situation of Anhui Haoyuan - As of the end of the first quarter of 2024, Anhui Haoyuan's total assets were RMB 797.34 million, total liabilities were RMB 584.89 million, and net profit was -RMB 113.37 million [6]. 5. Opinions from the Board and Supervisory Committee - The board and supervisory committee agree that the debt-to-equity conversion will not harm the interests of the company or its shareholders, particularly minority shareholders [7][8].